Background
PURPOSE 2 (NCT04925752) demonstrated the high efficacy and safety of twice-yearly subcutaneous (SC) lenacapavir (LEN) for pre-exposure prophylaxis (PrEP) in cisgender men and gender-diverse individuals who have sex with partners assigned male at birth and who are disproportionately affected by HIV. We report updated HIV incidence and safety data through the end of the randomized blinded phase of the study.
Methods
PURPOSE 2 is an ongoing Phase 3, double-blind, active-controlled, randomized clinical trial. Participants were randomized to receive either SC LEN every 26 weeks or daily oral emtricitabine-tenofovir disoproxil fumarate (F/TDF), with corresponding placebos. The primary efficacy analysis included data through August 2024. Following the primary analysis, participants completed visits through the end of the randomized blinded phase on a rolling basis through May 2025 and were given the option to join the LEN open-label extension. We assessed HIV incidence and adverse events through the end of the randomized blinded phase and measured LEN plasma concentrations in a single participant diagnosed with HIV in the LEN group after the primary analysis.
Results
Among 3265 participants who were HIV negative at baseline, 2179 were randomized to the LEN group and 1086 to the F/TDF group. After primary analysis, there was 1 additional HIV acquisition in the LEN group and 3 additional HIV acquisitions in the F/TDF group, for a total of 15 incident HIV infections observed through the end of the randomized blinded phase (3 in the LEN group and 12 in the F/TDF group). This corresponds to an updated HIV incidence of 0.11/100 person-years (PY) (95% CI: 0.02-0.33) in the LEN group and 0.93/100 PY (95% CI: 0.48-1.62) in the F/TDF group (Fig). The participant diagnosed with HIV in the LEN group received their last LEN injection approximately 25 weeks prior and had a LEN plasma concentration of 14.2 ng/mL, slightly below the target inhibitory quotient 4 concentration. No new significant safety concerns with LEN were observed. Among participants on LEN, 84.5% reported injection site reactions (ISRs) versus 70.4% in the F/TDF + placebo injection group. Most participants (83.9%) reported Grade 1 or 2 LEN ISRs and discontinuations due to ISRs remained low (1.2%) through the end of the randomized blinded phase.
Conclusions
In this analysis with longer-term data, twice-yearly SC LEN remained safe and highly efficacious for HIV PrEP in cisgender men and gender-diverse individuals who have sex with men.
Table or Figure
